(NASDAQ: IBRX) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased IBRX securities between January 19, 2026 and March 24, ...

Did you buy IBRX securities between January 19, 2026, and March 24, 2026? -- Who: ImmunityBio, Inc. (NASDAQ: IBRX) -- What: Securities fraud class action lawsuit filed -- Class Period: January 19, ...

Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...

ImmunityBio's stock closed at $7.70 on Friday, marking a 6% gain that starkly contrasts with the company's current reality. The biotech firm is caught in a powerful tug-of-war between explosive ...

ImmunityBio, Inc. IBRX shares are trading higher Tuesday after the company announced that ANKTIVA is now available in Saudi ...

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the ...

If you are an investor in ImmunityBio and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

ImmunityBio has seen its price surge by 266 percent year-to-date—with shares already at $7.25 versus only $1.98 on December ...